DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Applicant’s election without traverse of Group I, claims 1-10, and the species agrochemical and tannic acid in the reply filed on 11/24/2025 is acknowledged. Claims 11-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 11/24/2025. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale , or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 , 7-10 is/are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Liu (WO 2019/137005). As the WO document is not in English, citations are made to the attached translation. Liu teaches a tannic acid/polyvinyl pyrrolidone nanoparticles loaded with curcumin (¶74-76). Tannic acid is a polyphenol component and meets the limitations of claims 7-9 . Curcumin is a polyphenol compound and meets the limitations of claims 3 and 5 . Polyvinyl pyrrolidone is a hydrophilic polymer and meets the limitations of claim 10 . As the nanoparticles are loaded with curcumin (¶ 74-76), the active ingredient (curcumin) is ‘captured’ in the chemical matrix of the tannic acid/polyvinyl pyrrolidone nanoparticles. As the compounds are molecules, the composition is an intermolecularly fabricated composition. Claim(s) 2 -3, 5 is/are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Liu (WO 2019/137005) as evidenced by Kim, J. Agric. Food Chem. 2003, 51, 1578-1581. The discussion with respect to Liu above is incorporated herein by reference. Curcumin is an agrochemical and meets the limitations of claim 2 . See Kim, abstract, pg. 1578. Claim(s) 2-3, 5-6 is/are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Liu (WO 2019/137005) as evidenced by Ukil , British Journal of Pharacology (2003) 139, 209-218. The discussion with respect to Liu above is incorporated herein by reference. Curcumin is a food flavoring compound and meets the limitations of claims 2 and 6 . See Ukil , title, abstract, pg. 210. Claim(s) 1-3, 7-10 is/are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Ersan, Colloids and Surfaces B: Biointerfaces 104 (2013) 75-82. Ersan teaches a composition of polyacrylamide, tannic acid, and tetracycline (Fig. 6, pg. 76) where acrylamide was polymerized in the presence of tannic acid (QMG extract) (pg. 76). Tetracycline was added for adsorption studies (pg. 76) corresponding to capturing the active ingredient. Tetracycline is an antimicrobial for humans and livestock (pg. 75) and thus is a pharmaceutaical and agrochemical and meets claim 2. Tetracycline is a polyphenol compound and thus meets claim 3. Tannic acid is a polyphenol and meets claims 7-9. Polyacrylamide is a hydrophilic polymer and meets claim 10. As the compounds are molecules, the composition is an intermolecularly fabricated composition. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim (s) 4 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ersan, Colloids and Surfaces B: Biointerfaces 104 (2013) 75-82. The discussion with respect to Ersan above is incorporated by reference. Ersan does not explicitly provide an example using oxytetracycline. However, Ersan states that oxytetracycline is an antibiotic analog of tetracycline (pg. 75). Additionally, oxytetracycline and tetracycline differ in structure by a single -OH group. Therefore, it would have been obvious to one of ordinary skill in the art to use oxytetracycline because oxytetracycline is a known analog of tetracycline (pg. 75) and because the structures (differing by a -OH group) and uses (as antibiotics) are similar and thus would be expected to have similar properties. See MPEP 2144.09. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT ROBERT C BOYLE whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-7347 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Monday-Thursday, 10am-4pm . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Arrie (Lanee) Reuther can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT (571)270-7026 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ROBERT C BOYLE/ Primary Examiner, Art Unit 1764